📰 Proffered Paper News
Proffered Paper News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Proffered Paper. Real-time updates on events, politics, business and more.
February 20, 2024
Targeting two independent Phase 2 clinical efficacy updates for darovasertib in neoadjuvant uveal melanoma in mid-2024, including from the Phase 2 IST and Phase 2 company-sponsored studyTargeting...
October 22, 2023
Investor Webcast to be held Sunday, October 22 at 12:30 p.m. Eastern Time...
October 18, 2023
During ESMO Congress 2023, sessions will focus on hot topics in therapeutic areas, such as the use of immunotherapies in both the neoadjuvant and adjuvant settings, as well as nontherapeutic topics, such as the needs of caregivers and advances in technology.
October 11, 2023
The march of immunotherapy into a wider range of malignancies, as well as the smarter use of chemotherapy and novel targeted drugs, will be among the key highlights at the ESMO Congress 2023.
October 10, 2023
First Phase 3 survival data from KEYNOTE-A39/EV-302 support potential benefit of combination approach in previously untreated locally advanced or metastatic urothelial cancer; data are selected for...
October 5, 2023
Key data from the Phase III PSMAfore trial has been selected for a Presidential session; PSMAfore is investigating PluvictoTM vipivotide tetraxetan) in the pre-chemotherapy setting for patients with...
September 27, 2023
/PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage research and development biotechnology company, today announced several...
July 21, 2023
/PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, is pleased to announce today that the company will...
May 9, 2023
The Menarini Group ("Menarini"), a leading Italian pharmaceutical and diagnostics company, and Stemline Therapeutics ("Stemline"), a wholly-owned subsidiary of the Menarini Group, announced today that